You just read:

Significant New Data for Anticancer Agent Halaven® (eribulin) in Soft Tissue Sarcoma Sub-Types Shows Overall Survival Benefit Compared to Dacarbazine

News provided by

Eisai

30 May, 2015, 12:30 BST